Johnson & Johnson (NYSE:JNJ) Notches Up after Talc Lawsuit Win
TipRanks (Fri, 19-Apr 3:36 PM ET)
Johnson & Johnson (NYSE:JNJ) Notches Up After Talc Win
TipRanks (Fri, 19-Apr 3:36 PM ET)
Catalyst Watch: Tesla, Boeing and General Motors brace for earnings fireworks
Seeking Alpha News (Fri, 19-Apr 3:00 PM ET)
WHO considering safety alert on Kenvue kids cough syrup (update)
Seeking Alpha News (Fri, 19-Apr 2:48 PM ET)
WHO considering safety alert on Kenvue kids cough syrup
Seeking Alpha News (Fri, 19-Apr 12:49 PM ET)
Johnson & Johnson wins trial over talc-related cancer claim in Florida
Seeking Alpha News (Fri, 19-Apr 11:51 AM ET)
Brexit Impact On Drugs - Rising Shortages in UK Highlight Brexit Challenges
Benzinga (Fri, 19-Apr 11:39 AM ET)
Benzinga (Fri, 19-Apr 10:17 AM ET)
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
Benzinga (Fri, 19-Apr 9:28 AM ET)
Dividend Roundup: Johnson & Johnson, Dell, Lowe’s, Qualcomm and more
Seeking Alpha News (Fri, 19-Apr 8:13 AM ET)
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.
Johnson & Johnson trades on the NYSE stock market under the symbol JNJ.
As of April 19, 2024, JNJ stock price climbed to $147.91 with 8,611,970 million shares trading.
JNJ has a beta of 0.57, meaning it tends to be less sensitive to market movements. JNJ has a correlation of 0.15 to the broad based SPY ETF.
JNJ has a market cap of $356.17 billion. This is considered a Mega Cap stock.
Last quarter Johnson & Johnson reported $21 billion in Revenue and $2.71 earnings per share. This fell short of revenue expectation by $-27 million and exceeded earnings estimates by $.07.
In the last 3 years, JNJ stock traded as high as $186.69 and as low as $143.13.
The top ETF exchange traded funds that JNJ belongs to (by Net Assets): VTI, VOO, SPY, IVV, VTV.
JNJ has underperformed the market in the last year with a return of -5.2%, while the SPY ETF gained +21.2%. In the last 3 month period, JNJ fell short of the market, returning -7.5%, while SPY returned +4.3%. However, in the most recent 2 weeks JNJ has outperformed the stock market by returning -3.0%, while SPY returned -3.5%.
JNJ support price is $144.35 and resistance is $147.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that JNJ stock will trade within this expected range on the day.